Whalesbook Logo

Whalesbook

  • Home
  • About Us
  • Contact Us
  • News

Hindalco Industries Reports 21.2% Profit Growth in Q2 FY26 Driven by Strong India Business

Commodities

|

Updated on 07 Nov 2025, 09:58 am

Whalesbook Logo

Reviewed By

Satyam Jha | Whalesbook News Team

Short Description:

Hindalco Industries Limited announced a consolidated profit after tax of ₹4,741 crore for the quarter ended September 2025, a 21.2% increase from the previous year. The growth was propelled by robust performance in its India business, effective cost management, and operational efficiencies across its segments. Revenue also saw a significant rise of 13% to ₹66,058 crore.
Hindalco Industries Reports 21.2% Profit Growth in Q2 FY26 Driven by Strong India Business

▶

Stocks Mentioned:

Hindalco Industries Limited

Detailed Coverage:

Hindalco Industries Limited, the metals flagship of the Aditya Birla Group, has reported a strong financial performance for the second quarter of the fiscal year 2026, which ended in September 2025. The company's consolidated profit after tax grew by 21.2% to ₹4,741 crore, up from ₹3,909 crore in the corresponding period of the prior year. This impressive growth was primarily attributed to the stellar performance of its India business, disciplined cost management, and enhanced operational efficiencies. Revenue from operations increased by 13% to ₹66,058 crore compared to ₹58,203 crore in the year-ago period.

The company's India aluminium upstream business delivered outstanding results with EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) of ₹4,524 crore, marking a 22% increase. The aluminium downstream segment also performed well, with EBITDA rising by 69% to ₹261 crore.

Novelis, Hindalco's global arm, reported flat shipments but maintained a resilient performance despite market headwinds.

Managing Director Satish Pai highlighted the company's sustained growth momentum amid global volatility, attributing success to its integrated business model, prudent capital allocation, and focus on cost optimisation. He also reiterated the company's commitment to its sustainability agenda, focusing on climate action, circularity, water stewardship, and biodiversity protection.

Impact This robust financial report is likely to be viewed very positively by investors, signalling strong operational performance and strategic execution by Hindalco Industries. The consistent growth in profitability and revenue, supported by strong segment-specific EBITDA improvements, suggests resilience and operational strength. This could translate into positive market sentiment and potentially an upward movement in the company's stock price. Rating: 7/10

Difficult Terms: EBITDA: Earnings Before Interest, Taxes, Depreciation, and Amortisation. It is a measure of a company's operating performance before accounting for financing, tax, and capital expenditure decisions.


Insurance Sector

Life Insurance Corporation of India Reports Strong H1FY26 Performance, Exceeding Expectations

Life Insurance Corporation of India Reports Strong H1FY26 Performance, Exceeding Expectations

Supreme Court Halts Time Limit for Motor Accident Claims, Impacting Insurance Sector

Supreme Court Halts Time Limit for Motor Accident Claims, Impacting Insurance Sector

LIC CEO Optimistic About Growth Despite GST and Regulatory Challenges

LIC CEO Optimistic About Growth Despite GST and Regulatory Challenges

Life Insurance Corporation of India Reports Strong H1FY26 Performance, Exceeding Expectations

Life Insurance Corporation of India Reports Strong H1FY26 Performance, Exceeding Expectations

Supreme Court Halts Time Limit for Motor Accident Claims, Impacting Insurance Sector

Supreme Court Halts Time Limit for Motor Accident Claims, Impacting Insurance Sector

LIC CEO Optimistic About Growth Despite GST and Regulatory Challenges

LIC CEO Optimistic About Growth Despite GST and Regulatory Challenges


Healthcare/Biotech Sector

Eli Lilly's Mounjaro Becomes India's Top-Selling Drug by Value Amidst Surging Demand for Weight-Loss Therapies

Eli Lilly's Mounjaro Becomes India's Top-Selling Drug by Value Amidst Surging Demand for Weight-Loss Therapies

Alembic Pharmaceuticals Secures USFDA Final Approval for Generic Blood Cancer Drug Dasatinib

Alembic Pharmaceuticals Secures USFDA Final Approval for Generic Blood Cancer Drug Dasatinib

Eli Lilly's Mounjaro Becomes India's Top-Selling Drug by Value Amidst Surging Demand for Weight-Loss Therapies

Eli Lilly's Mounjaro Becomes India's Top-Selling Drug by Value Amidst Surging Demand for Weight-Loss Therapies

Alembic Pharmaceuticals Secures USFDA Final Approval for Generic Blood Cancer Drug Dasatinib

Alembic Pharmaceuticals Secures USFDA Final Approval for Generic Blood Cancer Drug Dasatinib